Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 91 to 100 of 660 total matches.
New Drugs for Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jan 05, 1996 (Issue 965)
old with decreased bone mineral density showed that intranasal salmon calcitonin in a dose of 200 IU ...
Two new drugs alendronate (Fosamax - Merck) and salmon calcitonin nasalspray (Miacalcin - Sandoz) are now available in the USA for treatment of postmenopausalosteoporosis. A third drug for treatment of osteoporosis, a slow-release fluoridepreparation (Slow Fluoride -Mission Pharmacal), has been recommended for approvalby an advisory committee of the US Food and Drug Administration (FDA). Various formulationsof fluoride have been available in Europe for this indication for many years.
Extended-Release Carbamazepine (Equetro) for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005 (Issue 1205)
dosage of
extended-release carbamazepine in adults with acute
mania is 200 mg twice daily. During ...
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro, for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.
Ciclesonide (Omnaris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
, by esterases in the nasal mucosa.
CLINICAL STUDIES — Ciclesonide nasal spray 200
mcg once daily was superior ...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Dupilumab (Dupixent) for Asthma
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
soln in single- 100 mg lyophilized powder 100 mg/10 mL soln in 200 mg/1.14 mL, 300 mg/2 mL
dose ...
The FDA has approved the subcutaneously injected
monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of
patients ≥12 years old with moderate to severe
asthma with an eosinophilic phenotype or with oral
corticosteroid-dependent asthma. Dupilumab was
approved earlier to treat adults with moderate to
severe atopic dermatitis inadequately controlled with
topical therapies.
Over-the-counter (OTC) Cough Remedies
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001 (Issue 1100)
5%
Novahistine DMX Syrup
(GlaxoSmithKline)
Pseudoephedrine 60 mg Guaifenesin 200 mg
Alcohol 5 ...
The number of cough remedies available in the USA continues to multiply, but most products contain the same or similar ingredients in varying combinations. Most acute coughs do not require treatment with drugs, especially in children, and suppression of a productive cough may be harmful.
Which TNF Inhibitor for Rheumatoid Arthritis?
The Medical Letter on Drugs and Therapeutics • May 17, 2010 (Issue 1338)
$1604.18
(human/2002)
Certolizumab pegol – Cimzia (UCB) 200 mg vial; 200 mg/mL 400 mg
2
SC at 0, 2 ...
The FDA has approved five tumor necrosis factor (TNF) inhibitors for treatment of moderately to
severely active rheumatoid arthritis (RA). TNF-α is a pro-inflammatory cytokine involved in the pathogenesis of many systemic inflammatory disorders.
A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
The Medical Letter on Drugs and Therapeutics • Aug 31, 2015 (Issue 1476)
% (human)/
recombinant human hyaluronidase
solution in dual vial units containing
2.5 g/200 U, 5 g/400 U ...
Immune globulin (IgG) has been available for
administration intravenously once every 3-4 weeks
or subcutaneously once daily, once weekly, or every 2
weeks for treatment of primary immunodeficiencies.
Now the FDA has approved human immune globulin
10% with recombinant human hyaluronidase (HyQvia –
Baxter) for subcutaneous administration only every
3-4 weeks in adults with these disorders. The IgG
component of HyQvia is identical to Gammagard
Liquid, which was approved in 2005 for IV administration
and in 2011 for SC administration.
Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
$2352.00
vials (200 mg IgG/mL)
Hizentra5 (CSL Behring) 5, 10, 20, 50 mL single-use q1-14 days SC 25 mL/hr ...
The FDA has approved a subcutaneously administered
20% solution of human immune globulin (Cuvitru –
Shire) for replacement therapy in patients ≥2 years old
with a primary humoral immunodeficiency. Hizentra
(CSL Behring), another subcutaneously administered
20% immune globulin solution, was approved in 2010
for the same indication. The IgG component of Cuvitru
is similar to that of Gammagard Liquid and HyQvia, two
subcutaneously administered 10% immune globulin
formulations also manufactured by Shire and approved
for treatment of primary...
A New Testosterone Gel (Fortesta) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
with signs and symptoms of hypogonadism may
have levels ...
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 other gels.
Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
. May be available at some retail pharmacies for $4 for a 30-day supply.
5. Available in 100- and 200-mg capsules ...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and...